18983288589(微信同号)
18983288589(微信同号)
18908392210(微信同号)
18980413049
ChiCTR1800014885
尚未开始
/
/
/
2018-02-12
/
/
超重或肥胖
An educational program for Hong Kong Chinese post-menopausal women
A theory-based educational program to improve the cardiovascular health among Hong Kong Chinese post-menopausal women
1) To examine the effects of the educational intervention on knowledge of CV health, self-efficacy and exercise, and physical activity and dietary pattern; 2) To examine if the effects of the intervention on physical activity and dietary pattern are mediated through knowledge of CV health, and self-efficacy in diet and exercise; 3) To examine if a positive change in physical activity and dietary pattern can result in improvements on CV health outcomes (body weight, body fat mass percentage, WC, CVD risk, fasting blood glucose, lipid profile, high sensitivity CRP, adiponectin, and IGF-1), sleep quality and vasomotor symptoms among overweight Chinese post-menopausal women in Hong Kong.
随机平行对照
其它
After collecting baseline data, eligible participants will be randomly allocated to intervention or control group using a computer-generated random number sequence prepared by an independent statistician.
The research assistant responsible for data collection will be blinded for group allocations of participants.
General Research Fund, Hong Kong
/
144
/
2018-01-01
2020-08-31
/
1) Chinese post-menopausal women aged ≤65 years [post-menopause is defined as experience of amenorrhea not attributing to other causes for at least 12 months13]; 2) Being overweight or obese (BMI > 22.9 kg/m2) or with central obesity (WC > 80cm)41; 3) Able to give informed consent; 4) Attain at least 6 years of formal education.;
登录查看1) Being diagnosed with any cardiovascular disease; 2) Concurrently participating in another clinical trial, lifestyle/dietary intervention, or weight control program; 3) Concurrently using hormonal replacement therapy; 4) Known history of psychiatric disorders.;
登录查看香港中文大學那打素護理學院
/
约印创投2025-01-16
求实药社2025-01-16
Genhouse2025-01-16
IPHASE2025-01-16
动脉网2025-01-16
动脉网-最新2025-01-16
药明康德2025-01-16
药明康德2025-01-16
再鼎医药2025-01-16
Rimonci2025-01-15